These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26970319)

  • 1. A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry.
    Nambam B; Silverstein J; Cheng P; Ruedy KJ; Beck RW; Paul Wadwa R; Klingensmith G; Willi SM; Wood JR; Bacha F; Thomas IH; Tamborlane WV;
    Pediatr Diabetes; 2017 May; 18(3):222-229. PubMed ID: 26970319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study.
    Cengiz E; Cheng P; Ruedy KJ; Kollman C; Tamborlane WV; Klingensmith GJ; Gal RL; Silverstein J; Lee J; Redondo MJ; Beck RW;
    Pediatr Diabetes; 2017 Nov; 18(7):566-573. PubMed ID: 27758023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control and complications in patients with type 1 diabetes - a registry-based longitudinal study of adolescents and young adults.
    Carlsen S; Skrivarhaug T; Thue G; Cooper JG; Gøransson L; Løvaas K; Sandberg S
    Pediatr Diabetes; 2017 May; 18(3):188-195. PubMed ID: 26875589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium.
    Klingensmith GJ; Connor CG; Ruedy KJ; Beck RW; Kollman C; Haro H; Wood JR; Lee JM; Willi SM; Cengiz E; Tamborlane WV;
    Pediatr Diabetes; 2016 Jun; 17(4):266-73. PubMed ID: 25951940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry.
    Tamborlane WV; Chang P; Kollman C; Klingensmith GJ; Ruedy K; Gal RL; Van Name M; Bacha F; Willi S; Beck RW;
    Pediatr Diabetes; 2018 Dec; 19(8):1379-1384. PubMed ID: 30175440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry.
    Gregg B; Connor CG; Cheng P; Ruedy KJ; Beck RW; Kollman C; Schatz D; Cengiz E; Tamborlane WV; Klingensmith GJ; Lee JM;
    Pediatr Diabetes; 2016 Jun; 17(4):274-80. PubMed ID: 25940861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries.
    Klingensmith GJ; Lanzinger S; Tamborlane WV; Hofer SE; Cheng P; de Beaufort C; Gal RL; Reinehr T; Kollman C; Holl RW
    Pediatr Diabetes; 2018 Nov; 19(7):1156-1163. PubMed ID: 29923263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current clinical status, glucose control, and complication rates of children and youth with type 1 diabetes in Rwanda.
    Marshall SL; Edidin D; Sharma V; Ogle G; Arena VC; Orchard T
    Pediatr Diabetes; 2013 May; 14(3):217-26. PubMed ID: 23279222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis.
    Redondo MJ; Connor CG; Ruedy KJ; Beck RW; Kollman C; Wood JR; Buckingham B; Klingensmith GJ; Silverstein J; Tamborlane WV;
    Pediatr Diabetes; 2014 Jun; 15(4):294-302. PubMed ID: 23889707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry.
    Bacha F; Cheng P; Gal RL; Kollman C; Tamborlane WV; Klingensmith GJ; Manseau K; Wood J; Beck RW;
    Horm Res Paediatr; 2018; 89(1):47-55. PubMed ID: 29131017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009.
    de Beaufort CE; Lange K; Swift PG; Aman J; Cameron F; Castano L; Dorchy H; Fisher LK; Hoey H; Kaprio E; Kocova M; Neu A; Njolstad PR; Phillip M; Schoenle E; Robert JJ; Urukami T; Vanelli M; Danne T; Barrett T; Chiarelli F; Aanstoot HJ; Mortensen HB;
    Pediatr Diabetes; 2013 Sep; 14(6):422-8. PubMed ID: 22957743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis.
    Cengiz E; Connor CG; Ruedy KJ; Beck RW; Kollman C; Klingensmith GJ; Tamborlane WV; Lee JM; Haller MJ;
    Pediatr Diabetes; 2014 Jun; 15(4):287-93. PubMed ID: 23944865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Care delivery in youth with type 2 diabetes - are we meeting clinical practice guidelines?
    Amed S; Nuernberger K; Reimer K; Krueger H; Aydede SK; Ayers D; Collet JP
    Pediatr Diabetes; 2014 Nov; 15(7):477-83. PubMed ID: 24888460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database.
    Aronson R; Orzech N; Ye C; Goldenberg R; Brown V
    J Diabetes; 2016 Jan; 8(1):76-85. PubMed ID: 25565383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of metabolic control and QTc prolongation on all-cause mortality in patients with type 2 diabetes and foot ulcers.
    Fagher K; Löndahl M
    Diabetologia; 2013 May; 56(5):1140-7. PubMed ID: 23404446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment regimens and glycosylated hemoglobin levels in youth with Type 1 and Type 2 diabetes: Data from SEARCH (United States) and YDR (India) registries.
    Amutha A; Praveen PA; Hockett CW; Ong TC; Jensen ET; Isom SP; D'Agostino RBJ; Hamman RF; Mayer-Davis EJ; Wadwa RP; Lawrence JM; Pihoker C; Kahn MG; Dabelea D; Tandon N; Mohan V
    Pediatr Diabetes; 2021 Feb; 22(1):31-39. PubMed ID: 32134536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes.
    Nwosu BU; Villalobos-Ortiz TR; Jasmin GA; Parajuli S; Zitek-Morrison E; Barton BA
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1399-1408. PubMed ID: 33027052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.